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Gene fusions prevalent in prostate cancer (CaP) lead to the elevated expression of the ERG proto-
oncogene. ERG activation present in 50–70% of prostate tumors underscores one of the most
common oncogenic alterations in CaP. Despite numerous reports of gene fusions and mRNA
expression, ERG oncoprotein status in CaP still remains to be defined. Furthermore, development
of ERG protein-based assays may provide a new dimension to evaluation of gene fusions involving
diverse androgen-regulated promoters and the ERG protein-coding sequence. Through exhaustive
evaluations of 132 whole-mount prostates (261 tumor foci and over 200000 benign glands) for the
ERG oncoprotein nuclear expression, we demonstrated 99.9% specificity for detecting prostate
tumor cells using a highly specific anti-ERG monoclonal antibody. The ERG oncoprotein
expression correlated well with fusion transcript or gene fusion in randomly selected specimens.
Strong concordance of ERG-positive foci of prostatic intraepithelial neoplasia (PIN) with
ERG-positive carcinoma (82 out of 85 sections with PIN, 96.5%) affirms the biological role of
ERG in clonal selection of prostate tumors in 65% (86 out of 132) of patients. Conversely, ERG
negative PINs were associated with ERG-negative carcinoma. Taken together, the homogeneous
and strong ERG expression detected in individual tumors establishes the potential for ERG
oncoprotein-based stratification of CaP.
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Introduction
Prevalent gene fusions involving regulatory sequences of
the androgen receptor (AR) regulated prostate-associated
genes (predominantly TMPRSS2) and protein-coding
sequences of nuclear transcription factors in the ETS
gene family (primarily ERG), result in frequent
overexpression of ERG in prostate tumors.
1–5 Emerging
studies suggest oncogenic functions of ERG and ETV1 in
prostate cancer (CaP).
1,6–11 Previous studies including
our report have analyzed ERG gene fusions at genomic
or mRNA levels in the context of multi-focal CaP and
these data showed inter-tumoral heterogeneity within
the same prostate.
12–15 Despite numerous reports of gene
fusions and mRNA expression, ERG oncoprotein in CaP
still remains to be defined. Using an anti-ERG mono-
clonal antibody (ERG–MAb) developed by our group, a
global view of ERG oncoprotein expression has been
established in the context of multi-focal CaP.
Materials and methods
Cell culture and androgen treatment
LNCaP (ATCC, no. CRL-1740) cells were grown in RPMI-
1640 medium supplemented with 10% fetal bovine
serum and 2mM glutamine. Cells (2 10
6) were seeded
onto 10cm dishes and maintained for 5 days in media
containing 10% charcoal-stripped fetal bovine serum
(c-FBS; no. 100119 Gemini Bio-Products, Calabasas, CA,
USA). For androgen induction, fresh media was supple-
mented with 0.1nM R1881 or 1nM R1881 synthetic
androgen for 48h. VCaP cells (ATCC, no. CRL-2876)
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www.nature.com/pcanwere grown in DMEM medium supplemented with 10%
fetal bovine serum and 2mM glutamine. Cells (2 10
6)
were seeded onto 10cm dishes and maintained for 3
days in media containing 10% charcoal-stripped fetal
bovine serum. For androgen induction, fresh media were
supplemented with 0.1nM R1881 or 1nM R1881 for
another 48h. At the end of the incubation period, cells
were harvested and analyzed by western blots and by
microscopy.
ERG siRNA treatment of prostate cancer cells
VCaP cells were seeded onto 10cm tissue culture dishes
in DMEM medium containing 10% c-FBS for 3 days.
Cells were transfected with ERG siRNA or non-targeting
control RNA using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) as described before.
7 Twelve hours
after transfection with siRNAs, the cell culture medium
was replaced with DMEM containing 10% charcoal-
stripped serum and 0.1nM R1881 and maintained for
4 days before harvest and analysis by western blots and
microscopy.
Immunoblot analysis
Cells were lysed in M-PER mammalian protein extrac-
tion reagent (Thermo, Rockford, IL,USA) containing
protease and phosphatase inhibitor cocktails (Sigma,
St Louis, MO, USA). Proteins were measured with Bradford
Assay reagent (BioRad, Hercules, CA, USA) and lysates
equivalent to 25mg proteins were separated on NuPAGE
Bis-Tris (4–12%) gels (Invitrogen, Carlsbad, CA, USA)
and blotted onto PVDF membranes (Invitrogen). Im-
munoblot assays were performed with ERG–MAb
(CPDR) mouse monoclonal antibody generated against
immunizing polypeptide GQTSKMSPRVPQQDWLSQPP
ARVTI, anti-PSA (Cat # A056201–2, DAKO, Carpinteria,
CA, USA) and anti–tubulin (Cat no. sc-5286, Santa Cruz,
CA, USA) antibodies. Clustal W
16 alignment did not
reveal a significant homology of the ERG–MAb peptide
antigen with 29 other protein sequences belonging to the
human ETS family. Of note, FLI1 protein sequence,
which showed 48% identity with the ERG-immunizing
peptide was not recognized by the ERG–MAb (Supple-
mentary Figure S1).
Immunofluorescence assay
Cells were fixed in fresh 4% formaldehyde in phosphate-
buffered saline (PBS) and permeabilized in PBS-T (PBS
þ 0.1% Triton X-100) and then centrifuged onto glass
slides with a Cytospin 4 centrifuge. Cells were blocked in
PBS-NT20 (PBS supplemented with 0.1% Tween-20 and
1% normal horse serum (Vector Laboratories, Burlin-
game, CA, USA). After incubation with a primary
antibody, cells were rinsed and then treated with goat
anti-mouse Alexa-594 (Cat no. A11302, Invitrogen)
followed by DAPI staining. Images were captured using
a 40/0.65 N-Plan objective on a Leica DMIRE2 inverted
microscope equipped with a QImaging Retiga-EX CCD
camera (Burnaby, BC, Canada), operated by OpenLab
software (Improvision, Lexington, MA, USA). Images
were converted into color and merged by using Photo-
shop (Adobe, San Jose, CA, USA). For ERG peptide
competition experiments, the ERG–MAb antibody was
pre-incubated with 2000-fold molar excess of competing
or non-competing peptide on ice for 30min.
Prostate specimens
Under an Institutional Review Board-approved protocol,
radical prostatectomy specimens from patients enrolled
in the Center for Prostate Disease Research program
were obtained by pathologists within 30min after the
surgical removal of the specimens. Prostates were
processed as whole-mounts according to the Armed
Forces Institute of Pathology (AFIP) protocol.
15 From
each of 132 patients, one whole-mount cross section
containing one to four tumors (mostly two foci) was
selected and tumors represented different grades and
stages. Each tumor was separately diagnosed in the
prostatectomy specimens and slices with more than one
tumor focus represented separate tumors. The cohort
includes 50 stage and grade matched patients of whom
25 developed metastasis and 25 had no recurrence with a
mean follow up of 46.5 months with the intent to address
possible prognostic features of ERG. To assess the
relationship between mRNA and ERG oncoprotein data
specimens from patients were included from previous
studies investigating ERG transcripts by quantitative
RT-PCR or by GeneChip (2, 5).
Immunohistochemistry (IHC) for ERG
Following deparaffinization, 4mm sections were dehy-
drated and blocked in 0.6% hydrogen peroxide in
methanol for 20min. Sections were processed for antigen
retrieval in EDTA (pH 9.0) for 30min in a microwave
followed by 30min of cooling in EDTA buffer. Sections
were then blocked in 1% horse serum for 40min
followed by incubation with the ERG–MAb mouse
monoclonal antibody at a dilution of 1:1280 for 60min
at room temperature. Sections were incubated with the
biotinylated horse anti-mouse antibody at a dilution of
1:200 (Vector Laboratories, Burlingame, CA, USA) for
30min followed by treatment with the ABC Kit (Vector
Laboratories) for 30min. The color detection was
achieved by treatment with VIP (Vector Laboratories)
for 5min. Sections were then counterstained in hematox-
ylin for 1min, dehydrated, cleared and mounted. The
ERG–MAb staining was determined according to percent
of cells positive: up to 25% (1þ), 425–50% (2þ), 450–
75% (3þ) and 475% (4þ). The intensity was scored as
mild (1þ), moderate (2þ) and marked (3þ). A
combination of both measurements was calculated by
multiplying the percent of positive cells with the degree
of intensity, which resulted in a score. As, most of the
tumors showed positivity in over 75% of cells and the
intensity was uniform, we expressed the staining results
as ERG positive or negative.
Analysis of ERG mRNA by branched-chain DNA (bDNA)
signal amplification
One 4-mm thick section was selected from each of the 35
FFPE whole-mount prostate samples. Areas identified as
tumors were marked, removed by scraping and were
homogenized and processed as described previously
17
and in the Supplementary Materials and Methods. The
geometric mean of the expression of three housekeeping
Defining of the ERG oncoprotein in prostate cancer
B Furusato et al
229
Prostate Cancer and Prostatic Diseasesgenes (ACTB, B2M, RPL19) was determined and only
samples with this mean value of minimum three-fold
over background signal were included in the analysis.
The TMPRSS2–ERG expression data was normalized to
the geometric mean of the three housekeeping genes in
each sample. Samples with normalized TMPRSS2–ERG
expression over an arbitrary cutoff of 0.5 were consid-
ered positive for the fusion. The TMPRSS2–ERG expres-
sion data tightly correlated with similarly normalized
ERG mRNA expression in the same samples. The
blinded transcript expression data were then compared
with the protein expression data.
Figure 1 Detection of ERG oncoprotein by ERG–MAb in prostate cancer cells. (a) LNCaP cells treated with 0.1nM R1881 (lane 2) or 1nM
R1881 (lane 3) and VCaP cells treated with 0.1nM R1881 (lane 5) or 1nM R1881 (lane 6) were analyzed for ERG oncoprotein by using ERG–
MAb as described in Materials and Methods. LNCaP (lane 1) and VCaP cells (lane 4) were processed in parallel without R1881 served as
controls. (b) ERG oncoprotein was analyzed in VCaP cells transfected with non-targeting (NT) or ERG siRNA oligonucleotides. Cell lysates
were prepared 4 days after transfection with 50nM NTsiRNA (lane 1), 25nM NTsiRNA and 25nM ERG siRNA (lane 2) or 50nM ERG siRNA
oligonucleotides (lane 3). Twenty-five micrograms of cell lysates were separated on NuPAGE Bis-Tris (4–12%) gels, transferred onto PVDF
membrane and immunoblotted ERG–MAb. Identical samples were transferred onto PVDF membranes and probed with ERG–MAb, anti-PSA
and anti–tubulin antibodies. The apparent size of the ERG protein products in the western blots correspond to predicted molecular weights of
TMPRSS2 (exon 1)-ERG3 (exons from 8 to 16, GenBank accession number NM_001136154) or TMPRSS2 (exon 1)-ERG2 (exons from 8 to 16
lacking exon 12, GenBank accession number NM_004449). (c) VCaP cells transfected with either NT siRNA (left panel) or ERG siRNA (right
panel) were immunostained with mouse ERG–MAb followed by goat anti-mouse Alexa-594 (red). (d) VCaP cells were grown in DMEM
supplemented with 10% fetal bovine serum. Cells were incubated with ERG–MAb, pre-treated with competing or non-competing peptide.
(e) VCaP or LNCaP cells treated with or without 1nM of R1881 were analyzed for ERG oncoprotein by ERG–MAb. (f) Schematic
representation of the expression of ERG oncoprotein (IHC) and TMPRSS2–ERG fusion mRNA was determined in prostate tumors of 35 CaP
patients treated with radical prostatectomy by using bDNA assay as described in Materials and Methods. Consecutive tissue slides from
whole-mounted FFPE prostate specimens were used for the two assays in a blinded fashion. Green triangles represent positive ERG
oncoprotein staining, orange triangles represent the detection of TMPRSS2–ERG fusion mRNA. Hollow triangles indicate specimens with
undetectable ERG oncoprotein or TMPRSS2–ERG fusion transcript.
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Sensitivity and specificity of ERG oncoprotein expression
were analyzed for distinguishing all tumor foci from
benign glands in whole-mount prostates (261 tumor foci
and over 200000 benign glands). Chi square test was used
to test the association of ERG oncoprotein status with tumor
differentiation and Gleason score for individual tumors.
P-value of 0.05 was adopted as statistically significant. The
SAS version 9.2 was used for all data analyses.
Results
Characterization of ERG oncoprotein by ERG monoclonal
antibody in cancer cell lines
In TMPRRS2–ERG-positive VCaP cells, a mouse
monoclonal anti-ERG antibody, ERG–MAb recognized
predicted sizes of full length protein products (50–52kDa)
encoded by TMPRSS2–ERG2 and TMPRSS2–ERG3 fusion
transcripts (Figure 1 and Supplementary Figure S2).
As expected, ERG–MAb did not detect ERG
oncoprotein in LNCaP cells, which do not harbor
TMPRSS2–ERG fusion (Figure 1a and Supplementary
Figure S2b). To further show the specificity of ERG–MAb,
a significant inhibition of the endogenous ERG
oncoprotein was noted in ERG siRNA
7 transfected VCaP
cells (Figure 1b). ERG protein was also detected in tumor
cell lines (KG1, COLO 320, MOLT4) previously described
to express ERG (Supplementary Figure 2b). Specificity of
the ERG–MAb for ERG oncoprotein detection in VCaP
cells was further validated by immunofluorescence (IF)
assays (Figures 1c–e). These data together established the
specificity of the ERG–MAb in detecting ERG oncoprotein
in CaP cells.
Figure 2 Distribution of ERG oncoprotein in a patient’s whole-mount cross section of the prostate. (a) Whole-mount cross section of one
prostate with two tumors: left upper quadrant and right lower quadrant, H&E 1. (b) Same section as (a). The tumor in the left upper
quadrant is ERG negative, whereas the tumor in the right lower quadrant is ERG positive. Note that the entire tumor is positively outlined
including the irregularly infiltrating borders, ERG–MAb 1. (c) The tumor infiltrates as densely packed simple glands between benign
glands, H&E 20. (d) Same field as (c). Only tumor cells are positive for ERG. Note the strong reactivity in endothelial cells of the capillaries,
some of which are in intimate proximity to benign glands, ERG–MAb 20. (e) Native glands lined by secretory cells with nuclear anaplasia
and recognizable basal cells are diagnostic of high-grade prostatic intraepithelial neoplasia. They are associated with infiltrating carcinoma,
H&E 20. (f) Same field as Figure (e). The nuclei of both the prostatic intraepithelial neoplasia and infiltrating carcinoma, are positive for
ERG, but with variable intensity. Basal cells are negative. Note the uniformly strong nuclear staining in capillaries (arrows). (g) A cluster of
benign glands appears to be prominent based on the dark staining cytoplasm, H&E 20. (h) Same field as (g). Rare benign secretory cells
show nuclear reactivity, ERG–MAb 20. (i) Left upper quadrant tumor. Note benign glands in the lower left. H&E 1. The inset shows
infiltrating carcinoma at the left adjacent to a benign gland, H&E 20. (j) Same field as (i). The tumor is negative for ERG. In the inset, both
the benign gland and tumor are negative for ERG. ERG–MAb 1 inset ERG–MAb 20.
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fusion status in prostate specimens
To determine the clinical utility of ERG–MAb, it was critical
to establish the specificity of the ERG oncoprotein staining
in tumor specimens in relation to TMPRSS2–ERG fusion
status. A comparative analysis was performed on
consecutive tissue sections of the ERG oncoprotein positive
or negative FFPE specimens for the detection of TMPRSS2–
ERG mRNA. Analysis of 35 evaluable specimens revealed a
strong correlation between mRNA levels of TMPRSS2–
ERG fusion type A transcript and ERG oncoprotein
immunohistochemistry (Figure 1f). A concordance rate of
82.8% was noted between mRNA and protein data despite
the expected differences in the sensitivity as well as read-
outs of the two techniques. A comparative evaluation of
TMPRSS2–ERG gene fusion analysis by fluorescence in situ
hybridization (FISH) and ERG oncoprotein expression by
ERG–MAb IHC in 10 specimens revealed no discrepancies
(Supplementary Figure S3).
Expression map of the ERG oncoprotein in multi-focal
prostate cancer
To delineate the expression map of ERG in benign
glands, carcinoma and prostatic intraepithelial neoplasia
(PIN), we utilized one entire cross section of each whole-
mount radical prostatectomy from 132 patients with
prostatic carcinoma. Each tumor was individually
measured and graded. On average, one whole-mount
section (3.5 2.5cm or 4.0 3.5cm) is equivalent to
approximately 800–1400 tissue microarray cores of
1mm diameter. In addition to index tumors, most
of these cross sections contained benign prostatic tissue
of the peripheral and the transition/periurethral zone as
well as the urethra, utricle, ejaculatory ducts (Figures 2a
and b), and seminal vesicles. A single tumor was present
in 51 sections, and multiple individual tumors were
present in 81 sections. Tumor grade, pathological stage,
margin status and clinical data are summarized in
Supplementary Table S1. In prostatic adenocarcinomas
(Figures 2c and d) and in PIN (Figures 2e and f) the
epithelial cells showed nuclear staining. ERG was
positive in 117 of 261 (44.8%) individual tumors
(Table 1a). ERG oncoprotein expression was highly
specific (99.9%) in detecting carcinoma (Table 1a).
Of 132 specimens only six specimens showed rare
ERG-positive non-malignant cells. In three specimens, a
single group of benign glands (average seven glands,
raging from five to eight glands) each was positive
for ERG in addition to carcinoma (Figures 2g and h). In
Figure 2 Continued.
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aggregates of native glands (3–5 glands) with increased
cellularity and nuclear enlargement and mild atypia,
changes previously referred to as ‘low grade PIN’. Eight
of the nine anterior/transition zone tumors were
negative (Figures 2i and j). In all but five cases, over
85% of tumor cells showed moderate to strong nuclear
staining with cytoplasmic blush (Figures 2c and d).
Association of the ERG oncoprotein status was
evaluated with various clinico-pathological features
(Supplementary Table S1a and b). Although, ERG
expression did not show correlation with most clinico-
pathological features, when all of the tumor foci in a
given whole-mount section were taken into account,
higher Gleason sum and less-differentiated tumors
showed significant correlation with ERG-positive im-
munostaining (Table 1b).
Eighty-two of eighty-five (96.5%) evaluable specimens
with ERG-positive tumor foci contained ERG-positive
PIN lesions, and all of the ERG-positive PIN foci were co-
located with ERG-positive tumors (Table 2). Eighty-one
sections contained multiple tumors; in 15 of these all
tumors were positive; in 31 all tumor foci were negative
and in 35 some tumors were diffusely positive and others
completely negative. Thus, in a multi-focal tumor
context, 50 of 81 sections (61.7%) had one or more
ERG-positive tumors. In the 51 sections containing only
one tumor, 36 (70.6%) were ERG positive, and two of
these contained clones of completely ERG-negative
tumor cells embedded in the positive areas (Figures 3a
and b). A weak non-discriminatory cytoplasmic staining
was observed in all epithelial cell types (prostatic and
non-prostatic), which was consistent with the cell line
data (Figures 3c and d).
The ERG–MAb consistently detected ERG in the nuclei
of all endothelial cells (lympho/vascular), which served
as intrinsic positive control for the ERG IHC assay. ERG
expression in endothelial cells has also been noted
previously in other contexts; however, its significance
remains to be defined.
18–20 Endothelial cells can be easily
identified by ERG-positive nuclei in cells with very little
discernible cytoplasm in contrast to carcinoma, in which
most of the tumor cells have ERG-positive nuclei and
easily identifiable cytoplasm (Figures 2c and d). In ERG
negative poorly differentiated/Gleason pattern 4 or 5
carcinomas, positive nuclei of endothelial cells often
have a linear narrow distribution (Supplementary Figure
S4a and b).
Tumor cells with amphophilic cytoplasm were more
strongly positive than those with pale or foamy
cytoplasm (Supplementary Figure S5a and b). Three of
the four mucinous carcinomas were positive for ERG
(Supplementary Figure S5c and d). Only two of the five
tumors with a ductal component were positive for ERG
(Supplementary Figure S5e–h). One tumor with vacuo-
lated/signet ring-like appearance was positive for ERG.
The focus with lymphoepithelioma-like features was
negative. In seven patients with lymph node metastases
at the time of prostatectomy, the ERG expression
mirrored the expression status of the index tumor. Four
ERG-positive primary tumors had ERG-positive metas-
tases, and conversely, three ERG-negative primary
tumors had ERG-negative metastases (Supplementary
Figure S3). By FISH assay, ERG-positive primary tumors
(Supplementary Figure S3a) and the corresponding
metastases (Supplementary Figure S3b) showed identical
fusion patterns.
Basal cells, urothelial cells of the prostatic urethra and
periurethral prostatic ducts were non-reactive. Ejaculatory
Figure 2 Continued.
Table 1a Frequency of ERG oncoprotein expression in whole-
mount prostatectomy specimens
ERG Individual tumors Benign glands
Positive 117 22
Negative 144 200000
Specificity¼99.99%; Sensitivity¼44.83%; PPV 84.17% and NPV¼
99.93%
Sensitivity and specificity of the ERG oncoprotein nuclear staining
distinguishing tumor foci from benign glands in 132 whole-mounted prostate
sections (261 tumor foci and about 200,000 benign glands). Number of benign
glands represents an estimate based on counting of the number of
benign glands in three average size sections of this cohort (average 1550
benign glands/section) multiplied by 132 sections.
Table 1b Association of ERG oncoprotein status with tumor
differentiation and Gleason pattern of individual tumors (N¼261)
Tumor grade ERG status P-value
Negative (N¼144) Positive (N¼117)
Tumor differentiation
Gleason pattern 3
(Well differentiated)
100 (62.5%) 60 (37.5%) 0.0027
Gleason pattern 4/5
(moderate/poorly
differentiated)
44 (43.6%) 57 (56.4%)
Tumor Gleason sum 0.0094
6 100 (62.5%) 60 (37.5%)
7 26 (41.3%) 37 (58.7%)
8–10 18 (47.4%) 20 (52.6%)
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Prostate Cancer and Prostatic DiseasesTable 2 Summary of the ERG oncoprotein status in individual tumors of whole-mount prostate sections
Abbreviations: Red: ERG-positive IHC; Green: ERG-negative IHC; NP: not present in the section; LGPIN: ‘low grade PIN’; 1: ERG expression in PIN; Gleason score (7a:
3+4; 7b: 4+3) annotated in tumor columns (T1 to T4).
A comprehensive analysis of benign glands, PIN and tumor foci for ERG oncoprotein status is summarizedin theheat map. Eighty-two of eighty-five (96.5%) evaluable
specimens with ERG-positive tumors contained ERG-positive PIN lesions and most of the time focally ERG-positive PIN foci co-located with ERG-positive tumors. In
contrast, ERG-positive PIN foci were present inonly3 of 45 (6.6%) sections with ERG-negative tumors. In theentire study cohort of 132 cases, six cases( 4 . 5 % )w e r eE R G
positive in rare benign glands or in atypical (LGPIN) foci and four of the six cases had ERG-positive tumors.
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stroma, variants of glandular hyperplasia including
microacinar hyperplasia (synonyms: adenosis, atypical
adenomatous hyperplasia), sclerosing adenosis and basal
cell hyperplasia were all negative for ERG. Different
patterns of atrophy including proliferative inflammatory
atrophy and evolving or partial atrophy were also
negative for ERG.
Discussion
As the gene fusion events in CaP commonly involve
regulatory sequences of AR-regulated prostate-asso-
ciated genes, for example, TMPRSS2, SLC45A3 or
NDRG1 along with protein coding sequences of the
nuclear transcription factors in the ETS gene family
(ERG, ETV1, ETV4–6 and ELK4), the resultant protein
products are ETS-related oncogenic transcription factors
with ERG being the most common.
1 The ERG–MAb
described herein exhibits a high degree of specificity and
sensitivity in recognizing ERG oncoprotein. Positive
nuclear staining for the ERG oncoprotein is highly
specific (99.9%) in identifying tumor cells in 65% of
patients. Nuclear ERG staining is virtually absent in
benign epithelial cells. Overall 44.8% of all 261 individual
tumors were ERG positive in this cohort, whereas 70.6%
of 51 specimens with single tumor were ERG positive
and 62% of 81 specimens with more than one tumor were
ERG positive. Overall frequencies of ERG expression in
CaP specimens noted here are similar to the reported rate
of gene fusions involving ERG locus reviewed in Kumar
Sinha et al., and Clark and Cooper.
1,21 Furthermore, this
study points to the potential contribution of sample bias
in assessing frequency of ERG alterations in CaP. In
previous studies specificity and sensitivity of ERG
protein detection was not addressed due to limited
number of specimens examined.
6,22 In general, tumors
are either homogeneously positive or negative for ERG
expression. This study highlights the association (96.5%)
of ERG-positive PINs with ERG-positive tumors (Table 2).
Figure 3 ERG oncoprotein in carcinoma with heterogeneous expression and non-discriminatory staining of benign glands. (a) Tumor shows
a ‘diverse’ ERG expression pattern with ERG positive alternating with ERG negative clones, H&E 20. (b) Same field as (a). Although, the
tumor cells appear similar in the H&E-stained section, they differ in their ERG oncoprotein distribution, ERG–MAb 20. (c) Benign gland
with basal and secretory cells, H&E 20. (d) Same field as (c). The nuclei of the secretory and basal cells are negative for ERG. Note weak
cytoplasmic reactivity in the secretory cells. The endothelial cells show strong nuclear positivity for ERG, ERG–MAb 20.
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1,23,24 have shown lower fre-
quency of ERG fusion-positive PIN (15–20%), this study
of whole-mount prostate sections allows more compre-
hensive evaluation of PIN and tumors in the context of
ERG oncoprotein expression (Figure 4).
The rare ERG-positive benign glands and the rare
atypical native glands, referred to as low-grade PIN, may
harbor sub-morphological molecular alterations, parti-
cularly in view of their topographical relationship to PIN
and/or carcinoma. This finding is in agreement with
previous studies reporting the presence of TMPRSS2–
ERG fusion transcripts in rare instances of benign
prostatic glands.
12,15 The confirmation of TMPRSS2–
ERG fusions in these foci is challenging due to their small
size. When considering the high concordance rate
between ERG oncoprotein expression and TMPRSS2–
ERG gene fusion transcript status, one could employ the
ERG IHC as an excellent surrogate marker for gene
fusions leading to ERG overexpression. Thus, in addition
to complementing genomic and mRNA-based assays
ERG oncoprotein detection provides a significant ad-
vance in assessing ERG alterations in CaP. For example,
translational products resulting from genomic fusion
events of ERG protein-coding sequence and regulatory
sequence of any 50 fusion partners (TMPRSS2, SLC45A3 and
NDRG1)
3,25,26 can be detected by ERG–MAb. On the
practical side, evaluation of ERG protein by IHC will be
more rapid and informative for morphological assessment
of ERG oncogenic activation in ‘front-end’ pathology setting.
Among the currently used diagnostic markers, a-
methylacyl-CoA racemase detects approximately 80%
of prostatic carcinomas and a variety of other carcino-
mas.
27 However, the specificity of a-methylacyl-CoA
racemase is lower than that of the ERG, because 25–30%
of benign prostatic glands may stain for a-methylacyl-
CoA racemase. Thus, inclusion of ERG–MAb in a
diagnostic IHC panel may increase the specificity for
tumor detection. The strong positive reaction of
ERG–MAb in endothelial cells observed highlights many
more capillaries in the prostate than were previously
appreciated using conventional endothelial cell markers
(CD 31, CD 34 and Factor VIII-related antigens). How-
ever, this feature of ERG expression may cause some
difficulties in the interpretation of the ERG IHC staining.
For example, capillaries in intimate contact with glands
may suggest basal cell staining, or dilated capillaries with
reactive endothelium may mimic small tumor glands or
atrophy. This initial limitation can be overcome by
gaining experience recognizing ERG-positive vascular
patterns (Supplementary Figure S4a and b).
Although prognostic features of ERG alterations in
CaP remain to be better understood, both positive and
negative associations have been reported and reviewed
in Kumar Sinha et al. and Clark and Cooper.
1,21 In this
evaluation of ERG oncoprotein, when all of the tumor
foci in a given whole-mount section were taken into
account, higher Gleason sum and less-differentiated
tumors showed correlation with ERG immunostaining
(Table 1b). However, there was no significant correlation
with progression (Supplementary Figure S6). Consider-
ing the ERG expression in the multi-focal tumor context,
further independent evaluations in larger and better-
defined cohorts are warranted.
In summary, among the currently known CaP protein
biomarkers the detection of the homogeneous, strong
and highly specific ERG oncoprotein offers unprece-
dented opportunities in CaP diagnostic setting. These
findings substantiate the role of ERG activation in clonal
selection and expansion of ERG-positive tumor cells
during the transition from pre-invasive to invasive CaP
in two-thirds of patients. Finally, with a better under-
standing of ERG functions in prostate tumor biology,
ERG–MAb-based stratification of prostate tumors in the
future may be used in the context of imaging, targeted
therapy or monitoring efficacy of androgen ablation
therapy.
Figure 4 Schematic representation of the concordance of ERG status between PIN and carcinoma in whole-mount prostates. Two scenarios
of whole-mount radical prostatectomy specimens are represented with carcinoma and PIN areas are marked. (a) Specimens with ERG ( )
carcinoma (yellow areas) and ERG ( ) PIN foci (yellow triangles) in the same prostates. (b) Specimens with at least one ERG (þ) carcinoma
(red areas) and PIN foci (red triangles) in the same prostates.
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